Veeva sees shared data platforms accelerating global drug approvals
VEEV•An industry analysis identifies shared regulatory platforms as a way to accelerate drug approvals and reduce costs, while regional rules, outdated technology and inconsistent data formats remain barriers.
1. Shared regulatory platforms
A Nov. 13 industry analysis identifies shared regulatory platforms as a route to faster drug approvals and lower costs. Concurrent reviews could reduce delays from sequential approvals and cut duplicated analysis and data storage costs across health authorities. Regional rules, outdated technology and inconsistent data formats remain barriers, with wider adoption dependent on global standards and cross-sector collaboration.
